Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 ICU patients may face higher superbug risk

NCT ID NCT04378842

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether being in the ICU with COVID-19 made patients more likely to pick up dangerous, drug-resistant bacteria. Researchers tracked 368 critically ill adults to compare infection rates before and during the pandemic. The goal was to understand if COVID-19 changed the spread of these superbugs in ICUs, which can help hospitals improve safety measures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

368 people

The number who actually took part.

Started

May 2020

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients admitted to intensive care

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Expected ICU stay \> 48 hours * Rectal and nasal BMR screening performed \< 48 hours after admission to ICU Exclusion Criteria: * Patients aged \< 18 years Refusal to take part in the study ICU-stay \< 48 hours At least a second rectal and nasal BMR screening was not performed prior to ICU discharge (a posteriori exclusion criterion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 Critical Illness Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness SARS-COV2

Contacts and locations

Locations

  • CH LENS

    Lens, France

  • Ch Bethune

    Béthune, France

  • Chu Amiens Picardie

    Amiens, France

  • Grand Hopital de L'Est Francilien

    Jossigny, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hospices Civils de Lyon (Pierre Bénite,Edouard Herriot, La Croix Rousse)

    Lyon, France

  • Hôpital Roger Salengro, ICU, CHU Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.